iRegene Therapeutics
Business Services · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
High-tech Development Zone No. 9 Gaokeyu...Website
www.iregene.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About iRegene Therapeutics
Founded in 2017 by a team of international professionals, iRegene Therapeutics is the earliest biotech in the world to apply "Chemical induction" to precisely reprogram cell fate and optimize cellular functions. Leveraging this breakthrough platform, iRegene Therapeutics has built a robust pipeline targeting currently "incurable" diseases such as Parkinson's disease and blindness. As a leader in chemical induction, iRegene's proprietary system enables the efficient easy generation of human specific cell types with high purity, and enhanced functionality, pioneering the next generation of chemically derived cell therapies.Explore more
iRegene Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is iRegene Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if iRegene Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once iRegene Therapeutics has new funding data
Product Launch: Get notified when iRegene Therapeutics launches new products
Website visits: Recent activity has been detected on your website
iRegene Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if iRegene Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on iRegene Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at iRegene Therapeutics
Check if iRegene Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at iRegene Therapeutics
Find more new buyers
Company Profile Activity
Activity Insights
iRegene Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
iRegene Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about iRegene Therapeutics.
iRegene Therapeutics Tech Stack
iRegene Therapeutics News & Media
iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data
CHENGDU, China, Oct. 13, 2025 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both the NMPA and the FDA to treat Parkinson's disease (PD). Recently, NouvNeu001 Phase I clinical data were presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS). ExcelleiRegene Therapeutics Secures Series B+ Financing Following FDA Fast Track Designation for its Flagship Product NouvNeu001
CHENGDU, China, Sept. 9, 2025 /PRNewswire/ -- iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, announced on September 4th the successful completion of its Series B+ financing round, co-led by Northern Light Venture Capital, Chuangjing Capital, and OneHealth Haihe Capital, along with participation from other investors. In August 2025, NouvNeu001 received Fast Track Designation (FTD) from the U.S.NouvNeu001 Achieves Milestone with Successful Dosing of First Patient, Signaling Smooth Progress in iRegene Therapeutics' Multicenter Clinical Trial for Innovative Novel Parkinson's Disease Therapy
WUHAN, China, Feb. 5, 2024 /PRNewswire/ -- iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company's first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation period. It is reported that the multicenter, open-label clinical trial (Phase I/II) is meticulously crafted to systematically evaluate the safety, tolerability, and efficacy of stereotactic bilateral intracere
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding iRegene Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2017 by a team of international professionals, iRegene Therapeutics is the earliest biotech in the world to apply "Chemical induction" to precisely reprogram cell fate and optimize cellular functions. Leveraging this breakthrough platform, iRegene Therapeutics has built a robust pipeline targeting currently "incurable" diseases such as P... Read More
